Authors
Latest:
FDA Approves Brentuximab Vedotin for Cutaneous LymphomaThe FDA has approved brentuximab vedotin (Adcetris) for the treatment of primary cutaneous anaplastic large-cell lymphoma and CD30-expressing mycosis fungoides in patients who have received prior systemic therapy.
Latest:
CAR T-Cell Therapy in ALL: Formidible Challenges RemainAt the NCCN Annual Conference, Dr. Bijal Shah of Tampa’s Moffitt Cancer Center highlighted ongoing challenges in administration of CAR T-cell therapy.
Latest:
Managing CAR T-Cell Therapy in Patients With Hematologic MalignanciesStephanie Jackson, MSN, RN speaks with Cancer Network about the role oncology nurses play in managing patients with hematologic malignancies who are undergoing CAR T-cell therapy.
Latest:
CAR T-Cell Therapy in Non-Hodgkin Lymphoma PatientsDr. Copelan discusses the use of chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma patients and how these therapies might improve upon the current standard of care.
Latest:
Managing Cytokine Release Syndrome in Patients on CAR T-Cell TherapyAhead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Latest:
Pediatric Acute Lymphoblastic LeukemiaONCOLOGY discussed therapy options, including chimeric antigen receptor (CAR)-T-cell therapies for pediatric acute lymphoblastic leukemia (ALL), with Susan R. Rheingold, MD, Medical Director of the Oncology Outpatient Clinic and attending physician with the Cancer Center at Children’s Hospital of Philadelphia.
Latest:
Dylan Essner on Documentation Tools for CAR T-Cell TherapyDylan Essner discussed the implementation of documentation tools and CRS, ICANS and ICE flow sheets within CAR T-cell therapy.
Latest:
Stem Cell Therapy Studies in TBI and Stroke: Bijan Nejadnik, MDThe chief medical officer at SanBio discussed how the investigational agent SB623 is being studied in TBI and stroke, with future planned studies in Alzheimer disease.
Latest:
Stem Cell vs Gene Therapy Processes in Sickle Cell DiseaseA discussion of the course of gene therapy compared with stem cell therapy.
Latest:
Making Noise About "Silent" Mutations in Treating Skin CancerMelanoma and other types of skin cancer are among the many types of cancer poised to benefit greatly from genomic research that identifies susceptibilities and potential targets for genetic-based therapy. A recent paper in Pigment Cell & Melanoma Research suggests, however, that an entire category of genetic mutations – one that could be incredibly fruitful in terms of diagnosis and treatment – is largely being ignored.
Latest:
Stem Cell Therapy for Myasthenia GravisRefractory cases of myasthenia gravis can be relieved by a new treatment based on replacing a patient’s immune system with new one created from transplants of his own stem cells, Canadian researchers report.
Latest:
New Stem Cell Therapy May Treat Crohn's DiseaseStem cell transplants may be a new, revolutionary way to treat Crohn's disease.
Latest:
Stem Cell Therapy Could Stop MS for Many Years, But Funding is an IssueExperimental stem cell therapy using a patient's own stem cells could offer long-term relief for many patients with multiple sclerosis, though questions still remain regarding cost, patient selection, and efficacy.
Latest:
Growth Hormone Therapy Effective at Increasing Anemics' Height During ChildhoodFor children with Diamond-Blackfan Anemia (DBA) - an inherited condition defined by low red blood cell counts and limited progenitor cells in the bone marrow - growth hormone (GH) therapy was found to increase the short stature of patients - a symptom not widely analyzed.
Latest:
The Virtual Window: Clinical Trial Reports--April 2007The Clinical Trials reported in this issue include: PHASE I: 1) Cell Genesys and Medarex Remain Positive on Combination Immunotherapy Study 2) Active Biotech Achieves Success with TASQ for Prostate Cancer PHASE II: 1) Myriad Initiates Evaluation of Brain Cancer Drug that Crosses the Blood-Brain Barrier 2) Second Lung Cancer Trial Adds Data to Novel Therapy PHASE III: 1) Nexavar Could Soon Add Primary Liver Cancer to its Label 2) Point Therapeutics Provides Clinical Update for NSCLC Studies
Latest:
Jakob Dupont, MD, on ATA188’s Potential in All Forms of Multiple SclerosisThe global head of research and development at Atara Biotherapeutics discussed ATA188 ahead of anticipated data readouts this month.
Latest:
Shai Efrati, MD: Inducing Stem Cell Proliferation With Hyperbaric Oxygen TherapyThe director of the Sagol Center for Hyperbaric Medicine and Research at Yitzhak Shamir Medical Center discussed how hyperbaric oxygen therapy is being used to attempt to improve the damage from neurodegeneration.
Latest:
Stem Cell Therapy for Traumatic Brain Injury?Phase 2 trial results suggest the possibility of a treatment that may regenerate brain cells following TBI.
Latest:
Dr. Vasileiou on the Potential Role of ALVR109 for the Treatment of COVID-19Spyridoula Vasileiou, PhD, discusses the potential role of ALVR109, a SARS-CoV-2 virus–specific T-cell therapy, for the treatment of coronavirus disease 2019.
Latest:
Dr. Karmali on Optimizing Maintenance Therapy in Older Patients With MCLReem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.
Latest:
Dr. Luke on Future Research With T-Cell Therapy in MelanomaJason J. Luke, MD, FACP, discusses the future of T-cell therapy in melanoma.
Latest:
Trial of Triplet Regimen With Cabozantinib Plus Immunotherapy Is Planned in RCCInvestigators see potential in adding targeted therapy to dual immunotherapy for intermediate- and poor-risk patients with renal cell carcinoma. In the phase III COSMIC-313 trial, investigators aim to evaluate cabozantinib, nivolumab, and ipilimumab in patients with untreated advanced RCC.
Latest:
CLL1-Targeted CAR T-Cell Therapy Shows Early Promise in Pediatric AMLResults of a phase 1/2 trial show the feasibility of an approach targeting CLL1 in pediatric patients with relapsed or refractory acute myeloid leukemia.
Latest:
Dr. Bauml on KEYNOTE-055 Study for Patients With HNSCCJoshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the preliminary results of the KEYNOTE-055 study, which investigated pembrolizumab (Keytruda) after failure on platinum-based therapy and cetuximab in patients with head and neck squamous cell carcinoma.
Latest:
Dr. McDermott on the Promise of Pembrolizumab in Non-Clear Cell RCCDavid F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.
Latest:
Dr. Lee on Nanotechnology Combination Therapy in RCCBenjamin R. Lee, MD, chief, Division of Urology, University of Arizona College of Medicine-Tucson Department of Surgery, and director of the Genitourinary Cancer and Disease Oriented Strategic Planning Team, University of Arizona Cancer Center, discusses nanotechnology combination therapy for patients with renal cell carcinoma (RCC).
